Polytropic Influence of rs2295490 Genetic Polymorphism on Response to Antihypertensive Agents in Patients With Essential Hypertension.
Author
Zhou, JiecanHe, Fazhong
Sun, Bao
Liu, Rong
Gao, Yongchao
Ren, Huan
Shu, Yan
Chen, Xiaoping
Liu, Zhaoqian
Zhou, Honghao
Deng, Sheng
Xu, Heng
Li, Jianmin
Xu, Linyong
Zhang, Wei
Date
2019-03-27Journal
Frontiers in PharmacologyPublisher
Frontiers Media S.A.Type
Article
Metadata
Show full item recordAbstract
Tribbles homolog 3 (TRIB3) mediating signaling pathways are closely related to blood pressure regulation. Our previous findings suggested a greater benefit on vascular outcomes in patients carrying TRIB3 (251, A > G, rs2295490) G allele with good glucose and blood pressure control. And TRIB3 (rs2295490) AG/GG genotypes were found to reduce primary vascular events in type 2 diabetic patients who received intensive glucose treatment as compared to those receiving standard glucose treatment. However, the effect of TRIB3 genetic variation on antihypertensives was not clear in essential hypertension patients. A total of 368 patients treated with conventional dosage of antihypertensives (6 groups, grouped by atenolol/bisoprolol, celiprolol, doxazosin, azelnidipine/nitrendipine, imidapril, and candesartan/irbesartan) were enrolled in our study. Genetic variations were successfully identified by sanger sequencing. A linear mixed model analysis was performed to evaluate blood pressures among TRIB3 (251, A > G) genotypes and adjusted for baseline age, gender, body mass index, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol and other biochemical factors appropriately. Our data suggested that TRIB3 (251, A > G) AA genotype carriers showed better antihypertensive effect than the AG/GG genotype carriers [P = 0.014 for DBP and P = 0.042 for mean arterial pressure (MAP)], with a maximal reduction of DBP by 4.2 mmHg and MAP by 3.56 mmHg after azelnidipine or nitrendipine treatment at the 4th week. Similar tendency of DBP-change and MAP-change was found for imidapril (ACEI) treatment, in which marginally significances were achieved (P = 0.073 and 0.075, respectively). Against that, we found that TRIB3 (251, A > G) AG/GG genotype carriers benefited from antihypertensive therapy of ARBs with a larger DBP-change during the period of observation (P = 0.036). Additionally, stratified analysis revealed an obvious difference of the maximal blood pressure change (13 mmHg for the MAP between male and female patients with AA genotype who took ARBs). Although no significant difference in antihypertensive effect between TRIB3 (251, A > G) genotypes in patients treated with α, β-ADRs was observed, we found significant difference in age-, sex-dependent manner related to α, β-ADRs. In conclusion, our data supported that TRIB3 (251, A > G) genetic polymorphism may serve as a useful biomarker in the treatment of hypertension.Identifier to cite or link to this item
http://hdl.handle.net/10713/15043ae974a485f413a2113503eed53cd6c53
10.3389/fphar.2019.00236
Scopus Count
Collections
Related articles
- Assessment of Human Tribbles Homolog 3 Genetic Variation (rs2295490) Effects on Type 2 Diabetes Patients with Glucose Control and Blood Pressure Lowering Treatment.
- Authors: He F, Liu M, Chen Z, Liu G, Wang Z, Liu R, Luo J, Tang J, Wang X, Liu X, Zhou H, Chen X, Liu Z, Zhang W
- Issue date: 2016 Nov
- <i>TRIB3</i> rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension.
- Authors: He F, Sun B, Li L, Liu M, Lin W, Liu L, Sun Y, Luo Y, Wu L, Lu L, Zhang W, Zhou Z
- Issue date: 2020 Apr
- Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension.
- Authors: Zhang S, Mao G, Zhang Y, Tang G, Wen Y, Hong X, Jiang S, Yu Y, Xu X
- Issue date: 2005 Nov
- A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
- Authors: Palma Gámiz JL, Pêgo M, Contreras EM, Anglada MP, Martínez JO, Esquerra EA, Sagastagoitia Gorostiza JD, Iberian Multicenter Imidapril Study on Hypertension.
- Issue date: 2006 Dec
- Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
- Authors: Hallberg P, Karlsson J, Lind L, Michaëlsson K, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nyström F, Liljedahl U, Syvänen AC, Melhus H
- Issue date: 2004 May